We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 355

News Bytes - May 16, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The National Institutes of Health (NIH) Office of Biotechnology Activities proposes revising the "NIH Guidelines for Research Involving Recombinant


Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • Canada, European Union, United Kingdom, USA, Australia
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


NGOs request march-in rights for patented drug
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

Four non-governmental organizations (NGOs) have filed a petition with the National Institutes of Health (NIH) requesting that it grant march-in rights under the Bayh-Dole Act for a patented drug that they claim is “a federally funded invention that is much more expensive in the United States than in Canada, Europe or other high-income countries.”


Data standards partnership launched
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

The U.S. Food and Drug Administration (FDA) has launched a partnership with the Clinical Data Interchange Standards Consortium and Critical Path Institute to develop standardized definitions for individual diseases and the therapeutic approaches to treat them in an effort to transform the massive data streams from drug studies on specific diseases into usable information


Putative class alleges pharma statements about new drug violated securities laws
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts


Bipartisan bill introduced to end “pay-for-delay” agreements
  • Shook Hardy & Bacon LLP
  • USA
  • February 8 2013

U.S. Sens. Amy Klobuchar (D-Minn.) and Chuck Grassley (R-Iowa) have introduced a bill (S. 214) that would prohibit the manufacturers of brand-name


Amici add briefs on “pay-for-delay” issue to SCOTUS docket
  • Shook Hardy & Bacon LLP
  • USA
  • February 8 2013

As oral argument nears in a case before the U.S. Supreme Court addressing whether payments made to generic drug makers who agree to delay entry into


Annual report reveals need for biotech shift in focus to demonstrate drug value
  • Shook Hardy & Bacon LLP
  • USA
  • May 2 2013

According to Ernst & Young's 27th annual biotechnology industry report, the global biotechnology industry has continued its recovery, but small and


News Bytes - May 2, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • May 2 2013

The National Nanotechnology Coordination Office schedules a June 11-12, 2013, public workshop in Washington, D.C., "to obtain input from stakeholders


Pharmacy and hospital interests present comments on proposed compounding bill
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Proposed legislation (S. 959) that would give the U.S. Food and Drug Administration (FDA) the authority to oversee compounding pharmacies that ship